Egypt's multiple myeloma therapeutics market was valued at $23 Bn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $37 Bn in 2030. One of the main reasons propelling the growth of this market is growing awareness and diagnosis, technological advancements. The market is segmented by type, drug, and distribution channel. Some key players in this market are EIPICO, Amoun Pharmaceutical Company, Pharco Pharmaceuticals, Delta Pharma, MEMI Pharmaceuticals, and others.
The Egypt Multiple Myeloma Therapeutics Market was valued at $23 Bn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $37 Bn in 2030. Egypt is one of the largest markets for multiple myeloma therapeutics in the Middle East and North Africa (MENA) region. The market is characterized by a growing demand for novel and innovative therapies, especially with the increasing prevalence of multiple myeloma in the country. The Egyptian multiple myeloma therapeutics market is expected to grow significantly over the forecast period, driven by factors such as increasing investments in healthcare infrastructure, rising disposable income, and an aging population.
Market Growth Drivers
The prevalence of multiple myeloma is increasing in Egypt due to several factors, such as the aging population and exposure to certain chemicals. This is expected to drive the demand for multiple myeloma therapeutics in the country. The awareness about multiple myeloma is increasing in Egypt, which is leading to more patients being diagnosed at an early stage. This is expected to drive the demand for multiple myeloma therapeutics in the country. The development of new and advanced therapies for multiple myeloma, such as immunotherapies and targeted therapies, is expected to drive the growth of the multiple myeloma therapeutics market in Egypt. The Egyptian government has launched several initiatives to improve the healthcare infrastructure and services in the country. This is expected to increase the availability and accessibility of multiple myeloma therapeutics in the country. Healthcare expenditure in Egypt has been increasing in recent years, which is expected to drive the demand for multiple myeloma therapeutics in the country.
The healthcare infrastructure in Egypt is not well developed, and this can pose a challenge for the diagnosis and treatment of multiple myeloma. Patients in Egypt may not have access to the latest and most innovative therapies due to regulatory and financial barriers. There may be a lack of awareness and education about multiple myeloma among patients and healthcare providers, leading to delayed diagnosis and treatment. The cost of multiple myeloma treatment in Egypt may be high, making it difficult for some patients to access the necessary care. There may be a shortage of skilled healthcare providers, such as hematologists and oncologists, who specialize in the treatment of multiple myeloma. The political instability in Egypt may affect the healthcare system, leading to disruptions in the supply chain of drugs and medical equipment.
In Egypt, the Ministry of Health and Population is responsible for regulating and overseeing the healthcare sector, including the approval and regulation of pharmaceutical products. The Central Administration of Pharmaceutical Affairs (CAPA) is the body responsible for the registration and licensing of drugs, including those used in the treatment of multiple myeloma. In recent years, Egypt has implemented a number of healthcare reforms aimed at improving the quality and accessibility of healthcare services. These reforms include the introduction of a universal health insurance system and the expansion of healthcare facilities in underserved areas.
The healthcare system in Egypt is mainly divided into two sectors: the public sector, which provides free or low-cost healthcare services to the majority of the population, and the private sector, which offers more specialized and expensive medical services to those who can afford it. The government has implemented a number of initiatives to improve healthcare services, including the introduction of universal health insurance, the expansion of primary healthcare centers, and the establishment of new hospitals and clinics. However, the healthcare system in Egypt faces several challenges, including a shortage of healthcare providers, inadequate healthcare infrastructure, and limited financial resources.
In terms of reimbursement for multiple myeloma therapeutics, the Egyptian government provides some coverage for cancer treatment through the National Cancer Institute, which is a specialized hospital that offers cancer treatment services to patients free of charge. However, the availability of cancer treatments in Egypt is limited, and many patients may need to travel abroad to receive the latest and most effective treatments.
Private health insurance is also available in Egypt, but it is primarily used by higher-income individuals and does not typically cover the full cost of cancer treatment. As a result, many patients may face financial hardship when seeking treatment for multiple myeloma.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
188.8.131.52 Product Applications and Services
184.108.40.206 Recent Developments
220.127.116.11 Partnerships Ecosystem
18.104.22.168 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Distribution Channel
By End User (Revenue, USD Bn):
By Drug Class
Immunomodulatory Drugs (IMiDs)
One of the most common therapies used to treat myeloma is immunomodulatory drugs or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:
Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:
Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:
Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:
Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.
Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.
Other drug classes used to treat multiple myeloma include:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses